Massroor Pourcyrous1,2,3, Mohamad T Elabiad4, Divya Rana4, Kan P Gaston4, Linda DeBaer4, Ramasubbareddy Dhanireddy4,5. 1. Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN, USA. mpourcyr@uthsc.edu. 2. Department of Obstetrics & Gynecology, University of Tennessee Health Science Center, Memphis, TN, USA. mpourcyr@uthsc.edu. 3. Department of Physiology, University of Tennessee Health Science Center, Memphis, TN, USA. mpourcyr@uthsc.edu. 4. Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN, USA. 5. Department of Obstetrics & Gynecology, University of Tennessee Health Science Center, Memphis, TN, USA.
Abstract
BACKGROUND: The aim of this study was to investigate the association between race and severe neonatal opioid withdrawal syndrome (NOWS) in infants exposed to intrauterine opioids. METHODS: This is a prospective observational study on intrauterine opioid-exposed term infants. Exposure to opioids was based on maternal disclosure, urine, or umbilical cord drug screening. Severe NOWS was defined based on modified Finnegan scoring and the need for pharmacological intervention. RESULTS: One hundred and fifty mother-infant pairs, 60 Black and 90 White with history of opioid exposure during pregnancy, were included. More White than Black infants developed NOWS that required pharmacological treatment, 70 vs. 40%: RR = 1.75 (1.25-2.45). In adjusted analysis, there was no significant association between race and the development of severe NOWS in mothers who attended opioid maintenance treatment program (OMTP). However, in mothers who did not attend OMTP, White race remained a significant factor associated with the development of severe NAS, RR = 1.69 (1.06, 2.69). CONCLUSIONS: Severe NOWS that required pharmacological intervention was significantly higher in White than in Black infants born to mothers who did not attend OMTP. Larger studies are needed to evaluate the association between social as well as genetic factors and the development of NOWS. IMPACT: There is a significant association between race and development of severe NOWS.
BACKGROUND: The aim of this study was to investigate the association between race and severe neonatal opioid withdrawal syndrome (NOWS) in infants exposed to intrauterine opioids. METHODS: This is a prospective observational study on intrauterine opioid-exposed term infants. Exposure to opioids was based on maternal disclosure, urine, or umbilical cord drug screening. Severe NOWS was defined based on modified Finnegan scoring and the need for pharmacological intervention. RESULTS: One hundred and fifty mother-infant pairs, 60 Black and 90 White with history of opioid exposure during pregnancy, were included. More White than Black infants developed NOWS that required pharmacological treatment, 70 vs. 40%: RR = 1.75 (1.25-2.45). In adjusted analysis, there was no significant association between race and the development of severe NOWS in mothers who attended opioid maintenance treatment program (OMTP). However, in mothers who did not attend OMTP, White race remained a significant factor associated with the development of severe NAS, RR = 1.69 (1.06, 2.69). CONCLUSIONS: Severe NOWS that required pharmacological intervention was significantly higher in White than in Black infants born to mothers who did not attend OMTP. Larger studies are needed to evaluate the association between social as well as genetic factors and the development of NOWS. IMPACT: There is a significant association between race and development of severe NOWS.
Authors: Rajiv Balyan; Marc Mecoli; Raja Venkatasubramanian; Vidya Chidambaran; Nichole Kamos; Smokey Clay; David L Moore; Jagroop Mavi; Chris D Glover; Peter Szmuk; Alexander Vinks; Senthilkumar Sadhasivam Journal: Pharmacogenomics Date: 2017-02-17 Impact factor: 2.533
Authors: Hendrée E Jones; Sarah H Heil; Michelle Tuten; Margaret S Chisolm; Julianne M Foster; Kevin E O'Grady; Karol Kaltenbach Journal: Drug Alcohol Depend Date: 2012-12-29 Impact factor: 4.492
Authors: Elisha M Wachman; P K Newby; Joy Vreeland; John Byun; Anthony Bonzagni; Howard Bauchner; Barbara L Philipp Journal: J Addict Med Date: 2011-12 Impact factor: 3.702
Authors: Margaret M Benningfield; Amelia M Arria; Karol Kaltenbach; Sarah H Heil; Susan M Stine; Mara G Coyle; Gabriele Fischer; Hendrée E Jones; Peter R Martin Journal: Am J Addict Date: 2010 Sep-Oct